Events ❯ Conferences ❯ Medical Conferences ❯ World Conference on Lung Cancer

IASLC

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Randomized testing is now underway to confirm benefit and better define safety.

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort